{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:07:37Z","timestamp":1790352457266,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"FOU Fyrbodal"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.ejim.2015.03.009","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T03:02:47Z","timestamp":1428721367000},"page":"344-347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms"],"prefix":"10.1016","volume":"26","author":[{"given":"Anneli","family":"Enblom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Lindskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte","family":"Hersby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Tetu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Girodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Andr\u00e9asson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ejim.2015.03.009_bb0005","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ejim.2015.03.009_bb0010","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejim.2015.03.009_bb0015","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejim.2015.03.009_bb0020","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejim.2015.03.009_bb0025","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2015.03.009_bb0030","doi-asserted-by":"crossref","first-page":"874146","DOI":"10.1155\/2011\/874146","article-title":"Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms","volume":"2011","author":"Stein","year":"2011","journal-title":"Thrombosis"},{"issue":"9","key":"10.1016\/j.ejim.2015.03.009_bb0035","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20years. Gruppo Italiano Studio Policitemia","volume":"123","year":"1995","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ejim.2015.03.009_bb0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","article-title":"Is JAK2 V617F mutation more than a diagnostic index?: a meta-analysis of clinical outcomes in essential thrombocythemia","volume":"33","author":"Dahabreh","year":"2009","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.ejim.2015.03.009_bb0045","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3324\/haematol.12970","article-title":"Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain","volume":"93","author":"Ziakas","year":"2008","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.ejim.2015.03.009_bb0050","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb Res"},{"issue":"25","key":"10.1016\/j.ejim.2015.03.009_bb0055","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2015.03.009_bb0060","article-title":"Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history","volume":"3","author":"Gangat","year":"2014","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.ejim.2015.03.009_bb0065","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ejim.2015.03.009_bb0070","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/sj.leu.2404724","article-title":"Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ejim.2015.03.009_bb0075","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2015.03.009_bb0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ejim.2015.03.009_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.leu.2404048","article-title":"Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution","volume":"20","author":"Cervantes","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ejim.2015.03.009_bb0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.blre.2012.06.002","article-title":"Front-line therapy in polycythemia vera and essential thrombocythemia","volume":"26","author":"Barbui","year":"2012","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.ejim.2015.03.009_bb0100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/bjh.12117","article-title":"Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients","volume":"160","author":"Bonicelli","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ejim.2015.03.009_bb0105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ejim.2015.03.009_bb0110","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620515000928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620515000928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T12:29:40Z","timestamp":1537705780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620515000928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0953620515000928"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2015.03.009","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2015.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}